Cargando…
P971: EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP.
Autores principales: | Fazio, Francesca, Passucci, Mauro, Lisi, Chiara, Micozzi, Jacopo, Fianchi, Luana, Landro, Francesca DI, Za, Tommaso, Gumenyuk, Svitlana, Ferraro, Silvia, Anaclerico, Barbara, De Padue, Laura, Annibali, Ombretta, Rago, Angela, Piciocchi, Alfonso, Bongarzoni, Velia, Cupelli, Luca, Mengarelli, Andrea, De Stefano, Valerio, Martelli, Maurizio, Petrucci, Maria-Teresa |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10431385/ http://dx.doi.org/10.1097/01.HS9.0000970788.32107.b7 |
Ejemplares similares
-
P25 EFFECT OF DARATUMUMAB ON STEM CELL YIELDS IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA: REPORT FROM THE MULTIPLE MYELOMA LAZIO GROUP
por: Fazio, F., et al.
Publicado: (2023) -
Daratumumab combined with dexamethasone and lenalidomide or bortezomib in relapsed/refractory multiple myeloma (RRMM) patients: Report from the multiple myeloma GIMEMA Lazio group
por: Fazio, Francesca, et al.
Publicado: (2022) -
Daratumumab for the Treatment of Multiple Myeloma
por: Plesner, Torben, et al.
Publicado: (2018) -
Daratumumab in dialysis-dependent multiple myeloma
por: Jeyaraman, Preethi, et al.
Publicado: (2020) -
Alkaline phosphatase (alp) levels in multiple myeloma and solid cancers with bone lesions: Is there any difference?
por: Annibali, O., et al.
Publicado: (2020)